G01N 2800/107
Crystal induced conditions
Official title: Crystal induced conditions; Gout
G01N2800/107 (Crystal induced conditions) appears on 21 US grants and 34 published applications in this corpus.
Search patents in G01N- Granted patents
- 21
- Published applications
- 34
- Assignees
- 24
- Inventors
- 64
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 2 |
| 2013 | 0 | 1 |
| 2014 | 0 | 3 |
| 2015 | 1 | 0 |
| 2016 | 1 | 3 |
| 2017 | 2 | 3 |
| 2018 | 4 | 2 |
| 2019 | 0 | 3 |
| 2020 | 3 | 3 |
| 2021 | 1 | 3 |
| 2022 | 0 | 0 |
| 2023 | 2 | 2 |
| 2024 | 1 | 2 |
| 2025 | 1 | 1 |
| 2026 | 4 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy30 Jun 2026US 12,669,498 B2Horizon Therapeutics USA, Inc.
- Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid3 Mar 2026US 12,566,174 B2The Research Foundation for The State University of New York
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy24 Feb 2026US 12,560,596 B2Amgen Inc.
- Formulations and doses of pegylated uricase17 Feb 2026US 12,553,041 B2Cartesian Therapeutics, Inc.
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy7 Jan 2025US 12,188,927 B2Horizon Therapeutics USA, Inc.
- Gout diagnosis apparatus using nonlinear optics1 Oct 2026US 2026/0298907 A1Pusan National University Industry-University Cooperation Foundation
- Formulations and doses of pegylated uricase20 Aug 2026US 2026/0242769 A1Cartesian Therapeutics, Inc.
- Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy30 Apr 2026US 2026/0118349 A1Horizon Therapeutics USA, Inc.
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy22 Jan 2026US 2026/0023073 A1Horizon Therapeutics USA, Inc.
- Methods and kits for predicting infusion reaction risk and antibody mediated loss of response by monitoring serum uric acid during pegylated uricase therapy17 Jul 2025US 2025/0231181 A1Horizon Therapeutics USA, Inc.
Most cited
By later US patents
- Method and apparatus for detecting the presence of intraerythrocytic parasites80US 9,046,473 B2Abbott Point of Care Inc. · 2015
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy33US 9,377,454 B2Crealta Pharmaceuticals LLC · 2016
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy13US 10,139,399 B2Horizon Pharma Rheumatology LLC · 2018
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy13US 10,823,727 B2Horizon Pharma Rheumatology LLC · 2020
- Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy9US 11,639,927 B2Horizon Therapeutics USA, Inc. · 2023